Citations

Clear

6274 citation(s) found for "To, Andrew".

Population Pharmacokinetics of Z‐Endoxifen in Patients With Advanced Solid Tumors
Koubek, Emily J. , Ralya, Andrew T., Larson, Thomas R. , McGovern, Renee M., Buhrow, Sarah A. , Covey, Joseph M. , Adjei, Alex A. , Takebe, Naoko , Ames, Matthew M. , Reid, Joel M. , Goetz, Matthew P.

Mayo Clinic

The Journal of Clinical Pharmacology | March 31, 2022 | Volume: 62 | Issue: 9 | Pages: 1121-1131

10.1002/jcph.2053 | PMID 35358345 Get It

AbstractThe purpose of this study was to develop and validate a population pharmacokinetic model for Z‐endoxifen in patients with advanced solid tumors and to identify clinical variables that influence pharmacokinetic parameters. Z‐endoxifen‐HCl was administered orally once a day on a 28‐day cycle (±3 days) over 11 dose levels ranging from 20 to 360 mg. A total of 1256 Z‐endoxifen plasma concentration samples from 80 patients were analyzed using nonlinear mixed‐effects modeling to develop a population pharmacokinetic model for Z‐endoxifen. A 2‐compartment model with oral depot and linear elimination adequately described the data. The estimated apparent total clearance, apparent central volume of distribution, and apparent peripheral volume of distribution were 4.89 L/h, 323 L, and 39.7 L, respectively, with weight‐effect exponents of 0.75, 1, and 1, respectively. This model was used to explore the effects of clinical and demographic variables on Z‐endoxifen pharmacokinetics. Weight, race on clearance, and aspartate aminotransferase on the absorption rate constant were identified as significant covariates in the final model. This novel population pharmacokinetic model provides insight regarding factors that may affect the pharmacokinetics of Z‐endoxifen and may assist in the design of future clinical trials.
Clinical Presentation and Management of Methicillin-Resistant Staphylococcus aureus Pericarditis—Systematic Review
Radovanovic, Milan , Petrović, Marija , Hanna, Richard D. , Nordstrom, Charles W. , Calvin, Andrew D. , Barsoum, Michel K., Milosavljevic, Natasa, Jevtic, Dorde , Sokanovic, Mladen, Dumic, Igor , Jevtic, Djordje , Dumic, Igor , Calvin, Andrew D , Sokanovic, Mladen

Mayo Clinic

Journal of Cardiovascular Development and Disease | March 30, 2022 | Volume: 9 | Issue: 4 | Pages: 103

10.3390/jcdd9040103 | PMID 35448079 Get It

In the expanding era of antibiotic resistance, new strains of Staphylococcus aureus have emerged which possess resistance to traditionally used antibiotics (MRSA). Our review aimed to systematically synthesize information on previously described MRSA pericarditis cases. The only criterion for inclusion was the isolation of MRSA from the pericardial space. Our review included 30 adult and 9 pediatric patients (aged: 7 months to 78 years). Comorbid conditions were seen in most adult patients, whereas no comorbidities were noted amongst the pediatric patients. Pericardial effusion was found in 94.9% of cases, with evidence of tamponade in 83.8%. All cases isolated MRSA from pericardial fluid and 25 cases (64.1%) had positive blood cultures for MRSA. Pericardiocentesis and antibiotics were used in all patients. The mortality rate amongst adults was 20.5%, with a mean survival of 21.8 days, and attributed to multi-organ failure associated with septic shock. No mortality was observed in the pediatric population. In adult patients, there was no statistical difference in symptom duration, antibiotic duration, presence of tamponade, age, and sex in relation to survival. Conclusion: MRSA pericarditis often presents with sepsis and is associated with significant mortality. As such, a high clinical suspicion is needed to proceed with proper tests such as echocardiography and pericardiocentesis. In more than one third of the cases, MRSA pericarditis occurs even in the absence of documented bacteremia.
Mammographic Density Decline, Tamoxifen Response, and Prognosis by Molecular Characteristics of Estrogen Receptor–Positive Breast Cancer
Abubakar, Mustapha , Mullooly, Maeve , Nyante, Sarah J. , Pfeiffer, Ruth M. , Bowles, Erin J. Aiello , Cora, Renata , Bodelón, Clara , Butler, Eboneé N. , Butcher, Donna , Sternberg, Lawrence, Weinmann, Sheila , Glass, Andrew G., González, Amy Berrington de , Gierach, Gretchen L. , Nyante, Sarah , Aiello Bowles, Erin J , Butler, Eboneé , Sherman, Mark , Berrington de Gonzalez, Amy , Gierach, Gretchen L , Pfeiffer, Ruth M , Troester, Melissa A. , Sherman, Mark E.

Mayo Clinic

JNCI Cancer Spectrum | March 29, 2022 | Volume: 6 | Issue: 3 | Pages: No page available

10.1093/jncics/pkac028 | PMID 35583138 Get It

Abstract Background Mammographic breast density (MBD) decline post-tamoxifen initiation is a favorable prognostic factor in estrogen receptor (ER)–positive breast cancer (BC) and has potential utility as a biomarker of tamoxifen response. However, the prognostic value of MBD decline may vary by molecular characteristics among ER–positive patients. Methods We investigated associations between MBD decline (≥10% vs <10%) and breast cancer–specific mortality (BCSM) among ER–positive breast cancer patients aged 36-87 years at diagnosis treated with tamoxifen at Kaiser Permanente Northwest (1990-2008). Patients who died of BC (case patients; n = 62) were compared with those who did not (control patients; n = 215) overall and by tumor molecular characteristics (immunohistochemistry [IHC]–based subtype [luminal A–like: ER–positive/progesterone receptor [PR]–positive/HER2–negative/low Ki67; luminal B–like: ER–positive and 1 or more of PR–negative, HER2–positive, high Ki67] and modified IHC [mIHC]–based recurrence score of ER/PR/Ki67). Percent MBD was measured in the unaffected breast at baseline mammogram (mean = 6 months before tamoxifen initiation) and follow-up (mean = 12 months post-tamoxifen initiation). Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed from logistic regression models. All statistical tests were 2-sided. Results MBD decline was statistically significantly associated with reduced risk of BCSM overall (OR = 0.38, 95% CI = 0.15 to 0.92). This association was, however, stronger among women with aggressive tumor characteristics including luminal B–like (OR = 0.17, 95% CI = 0.04 to 0.73) vs A–like (OR = 0.74, 95% CI = 0.19 to 2.92); large (OR = 0.26, 95% CI = 0.08 to 0.78) vs small (OR = 0.41, 95% CI = 0.04 to 3.79) tumors; PR–negative (OR = 0.02, 95% CI = 0.001 to 0.37) vs PR–positive (OR = 0.50, 95% CI = 0.18 to 1.40) disease; and high (OR = 0.25, 95% CI = 0.07 to 0.93) vs low (OR = 0.44, 95% CI = 0.10 to 2.09) mIHC3 score. Conclusion The findings support MBD decline as a prognostic marker of tamoxifen response among patients with aggressive ER–positive BC phenotypes, for whom understanding treatment effectiveness is critical.
Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy
Miller, Devon , Livingston, J. Andrew , Park, Yeonhee , Posey, Kristi, Godbole, Sonia, Skubitz, Keith M. , Agulnik, Mark , Davis, Lara E. , Tine, Brian A. Van , Livingston, John A , Skubitz, Keith , Agulnik, Mark , Davis, Lara E , Van Tine, Brian A , Hirbe, Angela C , Parkes, Amanda , Robinson, Steven I. , Hirbe, Angela C.

Mayo Clinic

Cancer Medicine | March 28, 2022 | Volume: 11 | Issue: 18 | Pages: 3471-3478

10.1002/cam4.4707 | PMID 35343652 Get It

AbstractBackgroundSarcomas are rare diagnoses but are seen with relative frequency in adolescents and young adults and thus can present in pregnancy. We sought to study the administration of anthracyclines and/or ifosfamide in pregnancy‐associated sarcomas.Patients and MethodsWe conducted a multi‐institutional retrospective study, identifying sarcoma patients who received anthracyclines and/or ifosfamide during pregnancy. Chart review identified variables related to demographics, cancer diagnosis, therapies, and outcome of the patient and fetus. Wilcoxon rank‐sum test compared two independent samples.ResultsWe identified 13 patients at seven institutions with sarcoma who received anthracyclines and/or ifosfamide during pregnancy, including four bone sarcomas and nine soft tissue sarcomas diagnosed at a mean gestational age of 16.7 ± 5.9 weeks. Only nine patients had live births (9/13, 69.2%), with mean gestational age of 30.8 ± 3.8 weeks at delivery. The four patients with pregnancy loss all received both doxorubicin and ifosfamide, with chemotherapy initiated at 15.5 weeks as compared with 21.3 weeks for those patients with live births (p = 0.016).ConclusionIn this multi‐institutional study of sarcoma chemotherapy regimens administered during pregnancy, we found a high rate of fetal demise that was seen only in patients receiving both doxorubicin and ifosfamide and statistically more likely with chemotherapy initiation earlier in the second trimester. While limited by a small sample size, our study represents the largest study of sarcoma patients that received anthracyclines and/or ifosfamide in pregnancy thus far reported and supports development of an international registry to study concerns raised by our study.
Stent placement for transplant hepatic artery stenosis
Devcic, Zlatko , Paz‐Fumagalli, Ricardo , Lewis, Andrew R. , Desai, Kush

Mayo Clinic

No container title available | March 25, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1148/cases.20221048 Get It

Kaizen Process Improvement in Radiology: Primer for Creating a Culture of Continuous Quality Improvement
Flug, Jonathan A. , Stellmaker, Jessica A. , Sharpe, Richard E. , Jokerst, Clinton, Tollefson, Chris , Bowman, Andrew W. , Nordland, Michelle, Hannafin, Cathy L , Froemming, Adam T. , Jokerst, Clinton E , Tollefson, Chris D , Bowman, Andrew W , Flug, Jonathan A , Nordland, Michelle R.

Mayo Clinic

RadioGraphics | March 25, 2022 | Volume: 42 | Issue: 3 | Pages: 919-928

10.1148/rg.210086 | PMID 35333633 Get It

The development of ultra–high field MRI guidance technology for neuronavigation
Rusheen, Aaron E., Goyal, Abhinav, Owen, Robert L., Berning, Elise M., Bothun, Dane T., Giblon, Rachel E., Blaha, Charles D., Welker, Kirk M., Huston, John, Bennet, Kevin E., Oh, Yoonbae, Fagan, Andrew J., Lee, Kendall H., Giblon, Rachel , Rusheen, Aaron E., Goyal, Abhinav, Owen, Robert L., Berning, Elise M., Bothun, Dane T., Blaha, Charles D., Welker, Kirk M., Huston, John, Bennet, Kevin E., Oh, Yoonbae, Fagan, Andrew J., Lee, Kendall H.

Mayo Clinic

Journal of Neurosurgery | March 25, 2022 | Volume: 137 | Issue: 5 | Pages: 1265-1277

10.3171/2021.11.jns211078 | PMID 35334465 Get It

OBJECTIVE Magnetic resonance imaging at 7T offers improved image spatial and contrast resolution for visualization of small brain nuclei targeted in neuromodulation. However, greater image geometric distortion and a lack of compatible instrumentation preclude implementation. In this report, the authors detail the development of a stereotactic image localizer and accompanying imaging sequences designed to mitigate geometric distortion, enabling accurate image registration and surgical planning of basal ganglia nuclei. METHODS Magnetization-prepared rapid acquisition with gradient echo (MPRAGE), fast gray matter acquisition T1 inversion recovery (FGATIR), T2-weighted, and T2*-weighted sequences were optimized for 7T in 9 human subjects to visualize basal ganglia nuclei, minimize image distortion, and maximize target contrast-to-noise and signal-to-noise ratios. Extracranial spatial distortions were mapped to develop a skull-contoured image localizer embedded with spherical silicone fiducials for improved MR image registration and target guidance. Surgical plan accuracy testing was initially performed in a custom-developed MRI phantom (n = 5 phantom studies) and finally in a human trial. RESULTS MPRAGE and T2*-weighted sequences had the best measures among global measures of image quality (3.8/4, p < 0.0001; and 3.7/4, p = 0.0002, respectively). Among basal ganglia nuclei, FGATIR outperformed MPRAGE for globus pallidus externus (GPe) visualization (2.67/4 vs 1.78/4, p = 0.008), and FGATIR, T2-weighted imaging, and T2*-weighted imaging outperformed MPRAGE for substantia nigra visualization (1.44/4 vs 2.56/4, p = 0.04; vs 2.56/4, p = 0.04; vs 2.67/4, p = 0.003). Extracranial distortion was lower in the head’s midregion compared with the base and apex ( 1.17–1.33 mm; MPRAGE and FGATIR, p < 0.0001; T2-weighted imaging, p > 0.05; and T2*-weighted imaging, p = 0.013). Fiducial placement on the localizer in low distortion areas improved image registration (fiducial registration error, 0.79–1.19 mm; p < 0.0001) and targeting accuracy (target registration error, 0.60–1.09 mm; p = 0.04). Custom surgical software and the refined image localizer enabled successful surgical planning in a human trial (fiducial registration error = 1.0 mm). CONCLUSIONS A skull-contoured image localizer that accounts for image distortion is necessary to enable high-accuracy 7T imaging–guided targeting for surgical neuromodulation. These results may enable improved clinical efficacy for the treatment of neurological disease.
Differences in postoperative quality of life in young, early elderly, and late elderly patients undergoing surgical treatment for degenerative cervical myelopathy
Croci, Davide M., Sherrod, Brandon, Alvi, Mohammed Ali, Mummaneni, Praveen V., Chan, Andrew K., Bydon, Mohamad, Glassman, Steven D., Foley, Kevin T., Potts, Eric A., Shaffrey, Mark E., Coric, Domagoj, Knightly, John J., Park, Paul, Wang, Michael Y., Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L., Than, Khoi D., Gottfried, Oren N., Shaffrey, Christopher I., Virk, Michael S., Bisson, Erica F., Park, Paul , Alvi, Mohammed Ali , Alvi, Mohammed Ali , Croci, Davide M., Sherrod, Brandon, Alvi, Mohammed Ali, Mummaneni, Praveen V., Chan, Andrew K., Bydon, Mohamad, Glassman, Steven D., Foley, Kevin T., Potts, Eric A., Shaffrey, Mark E., Coric, Domagoj, Knightly, John J., Park, Paul, Wang, Michael Y., Fu, Kai-Ming, Slotkin, Jonathan R., Asher, Anthony L., Than, Khoi D., Gottfried, Oren N., Shaffrey, Christopher I., Virk, Michael S., Bisson, Erica F.

Mayo Clinic

Journal of Neurosurgery: Spine | March 25, 2022 | Volume: 37 | Issue: 3 | Pages: 339-349

10.3171/2022.1.spine211157 | PMID 35276658 Get It

OBJECTIVE Cervical spondylotic myelopathy (CSM) is a common progressive spine disorder affecting predominantly middle-aged and elderly populations. With increasing life expectancy, the incidence of CSM is expected to rise further. The outcomes of elderly patients undergoing CSM surgery and especially their quality of life (QOL) postoperatively remain undetermined. This study retrospectively reviewed patients to identify baseline differences and validated postoperative patient-reported outcome (PRO) measures in elderly patients undergoing CSM surgery. METHODS The multi-institutional, neurosurgery-specific NeuroPoint Quality Outcomes Database was queried to identify CSM patients treated surgically at the 14 highest-volume sites from January 2016 to December 2018. Patients were divided into three groups: young (< 65 years), early elderly (65–74 years), and late elderly (≥ 75 years). Demographic and PRO measures (Neck Disability Index [NDI] score, modified Japanese Orthopaedic Association [mJOA] score, EQ-5D score, EQ-5D visual analog scale [VAS] score, arm pain VAS, and neck pain VAS) were compared among the groups at baseline and 3 and 12 months postoperatively. RESULTS A total of 1151 patients were identified: 691 patients (60%) in the young, 331 patients (28.7%) in the early elderly, and 129 patients (11.2%) in the late elderly groups. At baseline, younger patients presented with worse NDI scores (p < 0.001) and lower EQ-5D VAS (p = 0.004) and EQ-5D (p < 0.001) scores compared with early and late elderly patients. No differences among age groups were found in the mJOA score. An improvement of all QOL scores was noted in all age groups. On unadjusted analysis at 3 months, younger patients had greater improvement in arm pain VAS, NDI, and EQ-5D VAS compared with early and late elderly patients. At 12 months, the same changes were seen, but on adjusted analysis, there were no differences in PROs between the age groups. CONCLUSIONS The authors’ results indicate that elderly patients undergoing CSM surgery achieved QOL outcomes that were equivalent to those of younger patients at the 12-month follow-up.
Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score
Pai, Rish K. , Hogan, Malcolm , Zou, Guangyong , Adeyi, Oyedele , Anstee, Quentin M. , Aqel, Bashar , Behling, Cynthia , Carey, Elizabeth J. , Feagan, Brian G. , McFarlane, Stefanie C., Noureddin, Mazen , Younossi, Zobair M. , Loomba, Rohit , Ratziu, Vlad , Anstee, Quentin M , Corey, Kathleen , Ma, C , Ratziu, Vlad , Loomba, Rohit , Ratziu, Vlad , Adeyi, Oyedele , Zou, Guangyong , Jairath, Vipul , Aqel, Bashar A. , Clouston, Andrew Donald , Corey, Kathleen E. , Kleiner, David Erwin , Ma, Christopher , Valasek, Mark A. , Harrison, Stephen A.

Mayo Clinic

Hepatology | March 25, 2022 | Volume: 76 | Issue: 4 | Pages: 1150-1163

10.1002/hep.32475 | PMID 35332569 Get It

Abstract Background and Aims The NASH Clinical Research Network histologic scoring system, the gold‐standard NASH histology assessment for clinical trials, has demonstrated intrarater and interrater variability. An expert panel in a previous systematic Research and Development/University of California Los Angeles (RAND/UCLA) study determined that existing histologic scoring systems do not fully capture NASH disease activity and fibrosis, and standardized definitions of histologic features are needed. We evaluated the reliability of existing and alternate histologic measures and their correlations with a disease activity visual analog scale to propose optimal components for an expanded NAFLD activity score (NAS). Approach and Results Four liver pathologists who were involved in the prior RAND/UCLA study underwent standardized training and multiple discussions with the goal of improving agreement. They were blinded to clinical information and scored histologic measures twice, ≥2 weeks apart, for 40 liver biopsies representing the full spectrum of NAFLD. Index intraclass correlation coefficient (ICC) estimates demonstrated intrarater (0.80–0.85) and interrater (0.60–0.72) reliability. Hepatocyte ballooning items had similar interrater ICCs (0.68–0.79), including those extending scores from 0–2 to 0–4. Steatosis measures (interrater ICCs, 0.72–0.80) correlated poorly with disease activity. Correlations with disease activity were largest for hepatocyte ballooning and Mallory‐Denk bodies (MDBs), with both used to develop the expanded NAS (intrarater ICC, 0.90; interrater ICC, 0.80). Fibrosis measures had ICCs of 0.70–0.87. Conclusions After extensive preparation among a group of experienced pathologists, we demonstrated improved reliability of multiple existing histologic NAFLD indices and fibrosis staging systems. Hepatocyte ballooning and MDBs most strongly correlated with disease activity and were used for the expanded NAS. Further validation including evaluation of responsiveness is required.
Predictors of functional impairment in bipolar disorder: Results from 13 cohorts from seven countries by the global bipolar cohort collaborative
Burdick, Katherine E. , Millett, Caitlin E. , Yocum, Anastasia K. , Altimus, Cara M. , Aubin, V. , Belzeaux, Raoul , Berk, Michael , Biernacka, Joanna M. , Blumberg, Hilary P. , Cleare, Anthony J. , Diaz‐Byrd, Claudia , Dubertret, Caroline, Étain, Bruno , Forester, Brent P. , Fullerton, Janice M. , Frye, Mark A. , Gard, Sébastien, Godin, Ophélia , Klaus, Federica , Martínez‐Arán, Anabel , Olié, Émilie , Olorunfemi, Phebe, Passerieux, Christine , Peters, Amy T. , Pham, Dániel , Polosan, Mircea , Potter, J. , Samalin, Ludovic , Shanahan, Megan, Strawbridge, Rebecca , Stuart, Amanda L. , Ueland, Torrill, Williams, Lana J., Yatham, Lakshmi N. , Young, Allan H. , Nierenberg, Andrew A. , McInnis, Melvin G. , Biernacka, Joanna , Blumberg, Hilary P , Cleare, Anthony J , Etain, B , Fullerton, Janice M , Peters, Amy T , Potter, Julia R , Sajatovic, Martha , Strawbridge, Rebecca , Vieta, Eduard , Williams, Lana J , Wrobel, Anna L , Nierenberg, Andrew A , Pham, Daniel , Yatham, Lakshmi N , Young, Allan H , Berk, Michael , McInnis, Melvin G , Millett, Caitlin E , Burdick, K E , Samalin, Ludovic , Andreassen, Ole A. , Dubertret, Caroline , Eyler, Lisa T. , Haffen, Emmanuel , Lagerberg, Trine Vik , Leboyer, Marion , McElroy, Susan L. , Mitchell, Philip B , Schwan, Raymund , Torres, Ivan J.

Mayo Clinic

Bipolar Disorders | March 24, 2022 | Volume: 24 | Issue: 7 | Pages: 709-719

10.1111/bdi.13208 | PMID 35322518 Get It

AbstractObjectivesPersistent functional impairment is common in bipolar disorder (BD) and is influenced by a number of demographic, clinical, and cognitive features. The goal of this project was to estimate and compare the influence of key factors on community function in multiple cohorts of well‐characterized samples of individuals with BD.MethodsThirteen cohorts from 7 countries included n = 5882 individuals with BD across multiple sites. The statistical approach consisted of a systematic uniform application of analyses across sites. Each site performed a logistic regression analysis with empirically derived “higher versus lower function” as the dependent variable and selected clinical and demographic variables as predictors.ResultsWe found high rates of functional impairment, ranging from 41 to 75%. Lower community functioning was associated with depressive symptoms in 10 of 12 of the cohorts that included this variable in the analysis. Lower levels of education, a greater number of prior mood episodes, the presence of a comorbid substance use disorder, and a greater total number of psychotropic medications were also associated with low functioning.ConclusionsThe bipolar clinical research community is poised to work together to characterize the multi‐dimensional contributors to impairment and address the barriers that impede patients' complete recovery. We must also identify the core features which enable many to thrive and live successfully with BD. A large‐scale, worldwide, prospective longitudinal study focused squarely on BD and its heterogeneous presentations will serve as a platform for discovery and promote major advances toward optimizing outcomes for every individual with this illness.